Prosthetic joint infections (PJI) are severe complications that arise after joint replacement surgeries. According to Talal Al-Jabri et al., 2024, it affects approximately 1-3% of patients. PJIs account for a significant proportion of revision arthroplasties, driving the demand for advanced therapeutic options. According to the prosthetic joint infections pipeline analysis by Expert Market Research, the market is witnessing a growing focus on targeted antibiotics, bacteriophage therapies, and biofilm-disrupting agents. The increasing burden of orthopedic surgeries and antibiotic resistance is accelerating research in this field. The prosthetic joint infections drugs pipeline is expected to expand steadily in the coming years.
Major companies involved in the prosthetic joint infections pipeline analysis include Trellis Bioscience LLC, Armata Pharmaceuticals, and others.
Leading drugs currently in the pipeline include TRL1068, AP-SA02, and others.
The rising number of joint replacement surgeries, escalating antimicrobial resistance, and advancements in therapies targeting biofilm-related complications are driving growth in the prosthetic joint infections drug pipeline.
The Prosthetic Joint Infections Pipeline Analysis Report by Expert Market Research gives comprehensive insights into prosthetic joint infections therapeutics currently undergoing clinical trials. It covers various aspects related to the details of each of these drugs under development for prosthetic joint infections. The prosthetic joint infections report assessment includes the analysis of over 100 pipeline drugs and 50+ companies. The prosthetic joint infections pipeline landscape will include an analysis based on efficacy and safety measure outcomes published for the trials, including their adverse effects on patients suffering from the condition, and alignment with prosthetic joint infections treatment guidelines to ensure optimal care practices.
The assessment part will include a detailed analysis of each drug, drug class, clinical studies, phase type, drug type, route of administration, and ongoing product development activities related to prosthetic joint infections.
Read more about this report - REQUEST FREE SAMPLE COPY IN PDF
Prosthetic joint infections (PJIs) are serious complications that occur when bacteria infect the area surrounding an implanted joint, such as a hip or knee prosthesis. These infections typically arise during surgery, post-operative wound exposure, or via bloodstream spread. Bacteria form biofilms on the prosthetic surface, making infections persistent and difficult to treat.
Prosthetic joint infections are treated through a combination of surgical interventions, such as debridement or revision surgery, and long-term antibiotic therapy tailored to the causative organism. In November 2024, PHAXIAM Therapeutics received FDA clearance to initiate its Phase II GLORIA study, evaluating anti-Staphylococcus aureus phage therapy combined with antibiotics as a novel treatment for prosthetic joint infections.
According to Talal Al-Jabri et al., 2025, prosthetic joint infections (PJIs) remain a major clinical challenge due to their complex presentation and lack of a single definitive diagnostic test. In 2019, 238,697 arthroplasties were performed in the United Kingdom, with a PJI incidence of 1-3%. PJIs carry a high burden, with treatment costs reaching EUR 21,937 per case and a five-year mortality rate rising to 21.12%. This highlights the urgent need for effective and targeted drug therapies.
This section of the report covers the analysis of prosthetic joint infections drug candidates based on several segmentations, including:
By Phase
The pipeline assessment report covers 50+ drug analyses based on phase:
By Drug Class
The prosthetic joint infections pipeline analysis report covers 50+ drug analyses based on drug classes:
By Route of Administration
The pipeline assessment report covers 50+ drug analyses based on the route of administration.
The report covers phase I, phase II, phase III, phase IV, and early-phase drugs. The coverage includes an in-depth analysis of each drug across these phases. According to EMR analysis, phase II, at 32%, covers a major share of the total prosthetic joint infection clinical trials. It is followed by phase IV, demonstrating strong post-marketing research and mid-stage development. Phase III accounts for 21%, showing progress toward late-stage validation. Phase I contributes 15.79%, indicating early clinical interest. These advancements highlight growing innovation and commitment, positively impacting the prosthetic joint infections market pipeline.
The drug molecule categories covered under the prosthetic joint infections pipeline analysis include small molecules, peptides, monoclonal antibodies, gene therapies, and polymer-based drug conjugates. The prosthetic joint infections report provides a comparative analysis of the drug classes for each drug in various phases of clinical trials for prosthetic joint infections.
Antibacterial drug therapies are emerging as a promising approach in the treatment of prosthetic joint infections. For instance, TNP-2092, a novel multi-target antibacterial agent by TenNor Therapeutics, is currently undergoing Phase II clinical trials. Administered via intra-articular injection, it directly targets biofilm-associated infections by inhibiting bacterial RNA polymerase, DNA gyrase, and topoisomerase IV, offering improved outcomes over conventional antibiotics.
The EMR report for the prosthetic joint infections pipeline covers the profile of key companies involved in clinical trials and their drugs under development. It provides a detailed prosthetic joint infections therapeutic assessment, analyzing the competitive dynamics of the clinical trial landscape. Below is the list of a few players involved in prosthetic joint infections clinical trials:
This section covers the detailed analysis of each drug under multiple phases, including phase I, phase II, phase III, phase IV, and emerging drugs for prosthetic joint infections. It includes product description, trial ID, study type, drug class, mode of administration, and recruitment status of prosthetic joint infections drug candidates.
TRL1068, sponsored by Trellis Bioscience LLC, is a fully human monoclonal antibody disrupting bacterial biofilms in prosthetic joint infections. This ongoing Phase 2 trial is assessing its efficacy and safety alongside the DAIR procedure in patients with chronic knee or hip infections. The study aims to enable prosthesis retention, eliminating the need for two-stage exchange arthroplasty.
AP-SA02 by Armata Pharmaceuticals is entering a Phase 1b/2a trial to evaluate its safety, tolerability, and pharmacokinetics in treating prosthetic joint infections (PJI). Sponsored by Armata, this study is examining AP-SA02, a bacteriophage-based therapy targeting Staphylococcus aureus, including MRSA. The drug has shown promising results in disrupting biofilms and enhancing antibiotic efficacy in resistant PJI cases.
*Please note that this is only a partial list; the complete list of drugs will be available in the full report.*
The Prosthetic Joint Infections Pipeline Analysis Report provides a strategic overview of the latest and future landscape of treatments for prosthetic joint infections. It provides necessary information for making informed investment decisions along with research, development, and strategic planning efforts. The stakeholders will benefit from the essential insights into prosthetic joint infections collaborations, regulatory environments, and potential growth opportunities.
Cementless Total Knee Arthroplasty Market Report and Forecast
Upto 15% Off
USD
$1999 $1799
$3099 $2789
$4599 $3909
$5999 $5099
*While we strive to always give you current and accurate information, the numbers depicted on the website are indicative and may differ from the actual numbers in the main report. At Expert Market Research, we aim to bring you the latest insights and trends in the market. Using our analyses and forecasts, stakeholders can understand the market dynamics, navigate challenges, and capitalize on opportunities to make data-driven strategic decisions.*
Get in touch with us for a customized solution tailored to your unique requirements and save upto 35%!
Explore our key highlights of the report and gain a concise overview of key findings, trends, and actionable insights that will empower your strategic decisions.
|
Scope of the Report |
Details |
|
Drug Pipeline by Clinical Trial Phase |
|
|
Route of Administration |
|
|
Drug Classes |
|
|
Leading Sponsors Covered |
|
|
Geographies Covered |
|
Mini Report
One User
USD 1,999
USD 1,799
tax inclusive*
Single User License
One User
USD 3,099
USD 2,789
tax inclusive*
Five User License
Five User
USD 4,599
USD 3,909
tax inclusive*
Corporate License
Unlimited Users
USD 5,999
USD 5,099
tax inclusive*
*Please note that the prices mentioned below are starting prices for each bundle type. Kindly contact our team for further details.*
Flash Bundle
Small Business Bundle
Growth Bundle
Enterprise Bundle
*Please note that the prices mentioned below are starting prices for each bundle type. Kindly contact our team for further details.*
Flash Bundle
Number of Reports: 3
20%
tax inclusive*
Small Business Bundle
Number of Reports: 5
25%
tax inclusive*
Growth Bundle
Number of Reports: 8
30%
tax inclusive*
Enterprise Bundle
Number of Reports: 10
35%
tax inclusive*
How To Order
Select License Type
Choose the right license for your needs and access rights.
Click on ‘Buy Now’
Add the report to your cart with one click and proceed to register.
Select Mode of Payment
Choose a payment option for a secure checkout. You will be redirected accordingly.
Gain insights to stay ahead and seize opportunities.
Get insights & trends for a competitive edge.
Track prices with detailed trend reports.
Analyse trade data for supply chain insights.
Leverage cost reports for smart savings
Enhance supply chain with partnerships.
Connect For More Information
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
We employ meticulous research methods, blending advanced analytics and expert insights to deliver accurate, actionable industry intelligence, staying ahead of competitors.
Our skilled analysts offer unparalleled competitive advantage with detailed insights on current and emerging markets, ensuring your strategic edge.
We offer an in-depth yet simplified presentation of industry insights and analysis to meet your specific requirements effectively.
Share